Trastuzumab - Research Grade Biosimilar, CAS [[180288-69-1]], Unconjugated, Monoclonal

Produktübersicht

• Artikelname: Trastuzumab - Research Grade Biosimilar, CAS [[180288-69-1]], Unconjugated, Monoclonal
• Artikelnummer: PRS-21-854
• Hersteller Artikelnummer: 21-854
• Alternativnummer: PRS-21-854-0.1
• Hersteller: ProSci
• Kategorie: Antikörper
• Immunogen: Humanized / ERBB2 (HER2, Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD_antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2,
• Konjugation: Unconjugated
• Alternative Synonym: NEU, NGL, HER2, TKR1, CD340, HER-2, VSCN2, MLN 19, c-ERB2, c-ERB-2, HER-2/neu

Produkteigenschaften

• Klonalität: Monoclonal
• Konzentration: batch dependent
• NCBI: 2064
• UniProt: P04626
• Puffer: PBS buffer pH 7.5
• Quelle: CHO cells
• Reinheit: >95%
• CAS Nummer: [180288-69-1]

Anwendungsbeschreibung

• Application Verdünnung: For research use only .
• Anwendungsbeschreibung: Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes